Omnicell Stock News

Style Box ETF report for SPSM

Omnicell (OMCL) could produce exceptional returns because of its solid growth attributes.

NEOGEN's (NEOG) latest acquisition of Genetic Veterinary Sciences, Inc. will bolster the global genomics business.

Omnicell (OMCL) could produce exceptional returns because of its solid growth attributes.

Omnicell, Inc. (NASDAQ:OMCL)s stock price gapped up prior to trading on Thursday . The stock had previously closed at $180.93, but opened at $186.48. Omnicell shares last traded at $182.13, with a volume of 930 shares changing hands. Several equities research analysts have recently commented on the stock. Wells Fargo & Company assumed coverage on []

Related Stocks: OMCL ,

NextGen's (NXGN) comprehensive solution suite was adopted by Monmouth to better cater to patients' medical and dental needs.

Wells Fargo & Company started coverage on shares of Omnicell (NASDAQ:OMCL) in a research report report published on Monday, The Fly reports. The firm issued an overweight rating and a $203.00 price objective on the stock. A number of other brokerages have also recently issued reports on OMCL. Craig Hallum increased their target price on [] The post Omnicell (NASDAQ:OMCL) Research Coverage Started at Wells Fargo & Company appeared first on ETF Daily News .

Conestoga Capital Advisors LLC lifted its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 3.8% during the 3rd quarter, HoldingsChannel reports. The firm owned 1,502,425 shares of the companys stock after purchasing an additional 55,400 shares during the quarter. Omnicell comprises 3.1% of Conestoga Capital Advisors LLCs investment portfolio, making the stock its 8th biggest []

Csenge Advisory Group acquired a new position in Omnicell, Inc. (NASDAQ:OMCL) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,384 shares of the companys stock, valued at approximately $365,000. A number of other hedge funds and other institutional investors []

CERN vs. OMCL: Which Stock Is the Better Value Option?

CERN vs. OMCL: Which Stock Is the Better Value Option?

Raymond James Trust N.A. lifted its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 17.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,521 shares of the companys stock after purchasing an additional 513 shares during the period. Raymond James Trust N.A.s holdings []

Brokerages expect that Omnicell, Inc. (NASDAQ:OMCL) will report sales of $310.11 million for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Omnicells earnings, with the highest sales estimate coming in at $310.91 million and the lowest estimate coming in at $309.30 million. Omnicell reported sales of $249.20 million in the same []

This article was originally published on TipRanks.com Medication management solutions provider Omnicell, Inc. The post Omnicell to Acquire ReCept for $100M appeared first on Smarter Analyst .